Akèy › Kansè ovè › Florid › Orlando
Etid klinik pou Kansè ovè nan Orlando, FL
22 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Orlando (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Advent Health, Orlando
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- AdventHealth Cancer Institute, Orlando
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · 16 mi lwen
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ap rekriteFaz 2
- Site 0308 - Advent Health, Orlando
- Site 0241 - Florida Cancer Specialist - North, Altamonte Springs · 9 mi lwen
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Ap rekriteEtid obsèvasyon
- Orlando Health, Orlando
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ap rekriteFaz 2
- Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623, Orlando
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- AdventHealth Orlando, Orlando
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Sara Cannon Research Institute Lake Nona, Orlando
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- Florida Cancer Specialists - Lake Nona, Orlando
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Ap rekriteFaz 3
- Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085), Orlando
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Ap rekriteFaz 3
- Advent Health, Orlando
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ap rekriteFaz 2
- Advent Health Cancer Institute, Orlando
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute - Lake Nona Florida, Orlando
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Ap rekriteFaz 1
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Ap rekriteFaz 1/2
- Florida Cancer Specialists, Orlando
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Ap rekriteFaz 3
- AdventHealth Cancer Institute, Orlando
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Orlando Health Cancer Institute, Orlando
- Health Central, Ocoee · 10 mi lwen
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Florida Cancer Specialists, Orlando
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Ap rekriteFaz 3
- AdventHealth Cancer Institute, Orlando
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Florida Cancer Specialists, Orlando
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Orlando
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #8, Orlando
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan Orlando
- Kansè Poumon ki pa ti selil44 etid
- Obèsite31 etid
- Kansè Metastatik29 etid
- Sipwa27 etid
- Maladi Alzheimer25 etid
- Dyabèt Tip 224 etid
- Kansè (tout kalite)24 etid
- Kansè nan tete23 etid
- Kolit Ulseratif22 etid
- Kansè poumon21 etid
- Kansè kolorektal19 etid
- Twoub depresif majè19 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.